STAT3 Signalling in Cancer: Friend or Foe

Dear Colleague,

Aberrantly-active Signal Transducer and Activator of Transcription (STAT)3 has long been strongly implicated in malignant transformation and the development of human tumors, with the prevailing knowledge that it dysregulates cellular gene expression leading to uncontrolled cell growth and survival, and promotes tumor progression. Further, new mechanisms of STAT3-mediated oncogenesis that extend beyond the traditional transcriptional function have also been reported in recent years. Notwithstanding, evidence is also emerging that leads to the suggestion that STAT3 maintains contradictory functions, and that in certain contexts the protein might regulate cellular events that promote cell death and suppress cell proliferation. These data together indicate the biological functions of STAT3 are far more complex than presently known and that the overall responses to STAT3-inhibiting drugs are likely to be context dependent. In this Issue of Cancers, “STAT3 Signaling in Cancer: Friend or Foe”, experts are invited to contribute original research papers or review articles that will provide further insights on the seemingly divergent functions of STAT3 in cellular processes.

Prof. Dr. James Turkson
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.